The FDA recently approved Covidien’s contrast delivery system with radiofrequency identification (RFID) technology, integrating the technology to create a system that is designed to enhance patient safety by reducing the risk of medical errors in radiology departments.
The contrast delivery system pairs its unit-dose Ultraject prefilled contrast media syringes with its Optivantage DH power injectors for an RFID-enabled contrast delivery solution that automatically captures, stores and transmits data between the Ultraject syringe and the Optivantage DH power injector using RFID transponders or tags.
April 18, 2024 
